Euclises Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel COX-2 inhibitors for use in treating certain cancers, pain, and inflammation, today announced that Bobby W. Sandage, Jr., Ph.D., Euclises’ Chief Executive Officer, will present at the 8th Annual Biotech Showcase 2016 conference on January 13, 2016 at 3:00 PM Pacific Time. Dr. Sandage will provide an overview of Euclises’ business and of the company’s lead oncology candidate, ECP-1014. The conference will be held at the Parc 55 Hotel in San Francisco, CA.
About Euclises Pharmaceuticals, Inc.
Euclises
Pharmaceuticals, Inc. is a biopharmaceutical company advancing novel
cyclooxygenase-2 (COX-2) inhibitors (EuclicoxibsTM) for use
in the treatment of cancer. Working with development partner Guangzhou
Institutes of Biomedicine and Health (GIBH), Euclises has selected a
clinical development candidate (ECP-1014) and is currently conducting
IND-enabling studies in preparation for human clinical trials. The
company is headquartered within the BioGenerator Labs at CORTEX and
supported by funding from Cultivation Capital, BioGenerator, Missouri
Technology Corporation, the St. Louis Arch Angels, and other investors.
For more information, visit the Euclises website at www.euclises.com.
Forward-Looking Statements
This press release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements are
those involving future events and future results that are based on
current expectations, estimates, forecasts, and projections as well as
the current beliefs and assumptions of the Company’s management. Words
such as “outlook,” “believes,” “expects,” “appears,” “may,” “will,”
“should,” “anticipates,” or the negative thereof or comparable
terminology, are intended to identify such forward-looking statements.
Any statement that is not a historical fact is a forward-looking
statement. Forward-looking statements are only predictions and are
subject to risks, uncertainties, and assumptions that are difficult to
predict. Therefore actual results may differ materially and adversely
from those expressed in any forward-looking statements. You should not
place undue reliance on forward-looking statements. The Company does not
assume any obligation to update the information contained in this press
release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160105006558/en/